Preventing Alzheimer's disease progression remains a critical unmet need for millions of people worldwide.
Today, nearly 44 million people have or are living with an Alzheimer’s related disease worldwide. It is estimated that the Alzheimer’s burden in the U.S. will triple from 5.3 million people today to 16 million by 2050 in the U.S. In 2014, the direct costs of caring for people living with the disease was estimated to total well over $210 billion in the U.S. alone. The Alzheimer's disease therapeutics and diagnostics market reached over $6.7 billion in 2016, with predicted high overall growth beyond 2020. Demographics, new therapeutics that go beyond treating symptoms and molecular diagnostics and imaging in early patient selection and prognosis will drive this growth.
Kalgene is developing a novel fusion protein therapeutic for slowing the progression of Alzheimer’s disease, with technology licensed from the National Research Council of Canada. The therapeutic targets the toxic soluble amyloid and the clinical program will focus on patients with early clinical signs of cognitive decline, before progressive neural damage causes dementia.
Today we’ve completed pre-clinical proof of concept work in partnership with the NRC and McGill University. These studies have shown that the development candidate passes through the blood brain barrier and rapidly induces CSF-amyloid-beta clearance. PET studies in rat models of the disease showed dramatic plaque removal. In an aged rat disease model, neuronal connectivity using diffusion weighted MRI was vastly improved, hippocampal volume was increased and no increase in micro-hemorrhages was observed.